|
SFRS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.46879952644952E-10 |
| Normal-vs-Stage3 |
8.88178419700125E-16 |
| Normal-vs-Stage4 |
2.06568095961757E-12 |
| Stage1-vs-Stage2 |
1.683250E-01 |
| Stage1-vs-Stage3 |
7.128200E-02 |
| Stage1-vs-Stage4 |
5.716200E-02 |
| Stage2-vs-Stage3 |
9.490000E-01 |
| Stage2-vs-Stage4 |
7.504000E-01 |
| Stage3-vs-Stage4 |
6.384200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.38910000011283E-07 |
| Normal-vs-Asian |
5.90590000237867E-08 |
| Caucasian-vs-AfricanAmerican |
7.011200E-01 |
| Caucasian-vs-Asian |
1.830400E-01 |
| AfricanAmerican-vs-Asian |
5.954000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.194600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
3.33066907387547E-16 |
| Normal-vs-Age(61-80Yrs) |
1.74749104076E-12 |
| Normal-vs-Age(81-100Yrs) |
1.025790E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.368180E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.313170E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.360200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.367400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.485370E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.716300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.171400E-04 |
| Classical-VS-Follicular |
6.445000E-03 |
| Classical-VS-Other |
3.353600E-01 |
| Classical-VS-Normal |
1.6251444634463E-12 |
| Tall-VS-Follicular |
2.655000E-01 |
| Tall-VS-Other |
4.235200E-01 |
| Tall-VS-Normal |
1.6681100944993E-12 |
| Follicular-VS-Other |
9.091000E-01 |
| Follicular-VS-Normal |
1.92634797002711E-12 |
| Other-VS-Normal |
4.035700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.55111512312578E-16 |
| Normal-vs-N1 |
1.35490000330307E-08 |
| N0-vs-N1 |
3.502000E-01 |
|
|
